ADIOS STUDY SURVEY
ADIOS refers to the ADaptIve Ocrelizumab dosing Study.

The ADIOS study proposes to explore whether or not we can adjust the dose of ocrelizumab to make it safer (lower rate of hypogammaglobulinaemia and fewer infections), allow vaccinations (for example SARS-CoV-2 vaccine), reduce healthcare utilisation (fewer infusions and lower costs) without necessarily compromising its efficacy.

This survey is to explore some issues around the principles of the study, our proposed design and whether or not you want to participate. The figure below is a rough outline of the proposed study.

Sign in to Google to save your progress. Learn more
Do you agree in principle with ADIOS study's aims?
Clear selection
Is the ADIOS study addressing an unmet need?
Clear selection
Could you please rate the main priorities for doing the ADIOS study? *
Scientific = to show that ocrelizumab can be used as an immune reconstitution therapy similar to alemtuzumab, Safety = to reduce the risk of infections and/or hypogammaglobulinaemia and to allow vaccination, Economic = to reduce NHS healthcare utilisation
4. High priority
3. Intermediate priority
2. Low priority
1. Not important
Scientific
Safety
Economic
Is the ADIOS study ethically justified?
Clear selection
Would you refer patients for randomisation into the ADIOS study?
Clear selection
Do you think we should have additional arms in the ADIOS study?
Clear selection
Next
Clear form
Never submit passwords through Google Forms.
This form was created inside of Gavin Giovannoni.

Does this form look suspicious? Report

Google Forms